Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0030193 (pain)
 261,466 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A previously healthy 12-year-old boy developed pain on walking and x-rays showed osteoporosis. Over the next 2 years deterioration occurred, the condition became extremely severe, and he was confined to a wheelchair. After 5 years, marked kyphoscoliosis and pigeon chest deformity were present and little increase in height occurred. A wheelchair accident at the age of 17 resulted in several major long bone fractures. Iliac crest biopsies were taken at ages 15 and 17, and subjected to quantitative histology. A histochemical technique for osteoclast recognition by acid phosphatase activity showed resorption parameters to be normal. Double tetracycline labeling and histochemical identification of osteoblasts showed no abnormality of endosteal bone formation. Because of "coupling" of endosteal formation and resorption, these measurements might primarily reflect bone turnover. Failure of periosteal bone formation as shown by failure of radial growth of long bones and of epiphyseal growth was clearly evident. It is likely that osteoporosis developed in this patient due to a reduction in bone formation of unknown etiology rather than by increased bone resorption.
 ...
PMID:Bone metabolism in idiopathic juvenile osteoporosis: a case report. 683 91

Acid phosphatase activity in the rat substantia gelatinosa has been shown to increase in response to a formalin-induced painful stimulus. In the rat the substantia gelatinosa is the location of the first synapse in the pain pathway. One site of morphine's analgesic effect is at this first synapse. The present study shows that morphine blocks the previously observed increase in acid phosphatase activity during a painful stimulus. Naloxone antagonizes the morphine effect. These results point to a possible functional role of acid phosphatase in the afferent transmission of pain signals.
 ...
PMID:Morphine blocks the increase in acid phosphatase in the substantia gelatinosa during pain. 684 6

Cyclophosphamide and prednisolone therapy was given to 83 patients with hormone-resistant disseminated carcinoma of the prostate. In 7 cases there were objective signs of regression of metastases. Significant reduction of elevated acid phosphatase activity was recorded in 11 cases, in 2 of them to normal range. 55 patients experienced pain relief, 26 of them very good. In the majority of cases duration of the remission was shorter than 6 months, in 2 cases it lasted more than a year.
 ...
PMID:Cyclophosphamide-prednisolone therapy in advanced prostatic carcinoma. 693 21

Chlorambucil plus prednisolone were administered to 11 patients with metastasis hormone refractory prostatic cancer, and the results were contrasted with a previously reported series of 23 similar patients treated with the chemical conjugate of these two agents, known as prednimustine or Leo 1031. The conjugated form of treatment (Leo 1031) had a limited therapeutic advantage, in that 3 patients experienced shrinkage of an enlarged prostate, 2 of whom also had elevated acid phosphatase levels return to normal and 5 others experienced only subjective improvement. There were, however, more adverse side effects in this group than those noted in patients treated with the combination of agents. Patients treated with the combination of drugs experienced no appreciable tumor shrinkage and none had acid phosphatase return to normal, although some reduction was noted in 8 of 11 patients who had elevated levels initially. Two of the 11 patients were considered stable for twelve months and one other remained ambulatory with mild pain for six months. Thus, to the degree that these studies permit, it is judged that the conjugated agent may have some limited therapeutic advantage not observed when the unconjugated agents were used.
 ...
PMID:Chemotherapy in metastatic, hormone refractory prostatic cancer using chlorambucil in combination with prednisolone versus conjugate, prednimustine (Leo 1031). 701 69

Two-day and 15-day-old offspring of capsaicin-pretreated Wistar rats were given subcutaneous injections of a 5% formalin solution to the dorsal aspect of the right forepaw. One hour after injection, acid phosphatase activity of the substantia gelatinosa of formalin/capsaicin cervical sections was significantly greater bilaterally than in saline/capsaicin 15-day-old animals. In 2-day-old animals the formalin/control right cervical sections had significantly higher acid phosphatase activity than saline/control. These results are further support for a direct functional relation between activity in the substantia gelatinosa and chemogenic pain stimulus.
 ...
PMID:Changes in acid phosphatase activity in the substantia gelatinosa in response to pain. 709 67

Twenty-three patients with advanced prostate cancer who had failed previous hormone therapy were treated with cyclophosphamide, doxorubicin, and methotrexate on a 3-week course. Of the 22 evaluable patients, over one-half had poor performance status, increased acid and alkaline phosphatase levels, and pain. Parameters which improved in greater than 50% of cases included acid and alkaline phosphatase levels, pain, performance status, and measurable lesions (lung and soft tissue). Initial parameters associated with a significantly decreased survival were age greater than 66 years, increased pain, poor performance status, and increasing alkaline phosphatase. Prior radiation therapy was associated with increased drug toxicity, lower doses of chemotherapy, and decreased survival (not significant). There was a significant relationship between the degree of improvement of acid phosphatase, alkaline phosphatase, pain, and performance status to increased survival. Three categories of response were defined based on these parameters. The mean survival of seven patients with partial response (106 weeks) is significantly longer than that of seven with measurable response (57 weeks) and eight with no response (26 weeks). Four patients had severe leukopenia and one died of sepsis. These results compare favorably with previous reports of chemotherapy treatment of advanced prostate cancer.
 ...
PMID:Treatment of advanced prostate cancer with cyclophosphamide, doxorubicin, and methotrexate. 712 21

Apart from an occasional focal lesion, ureteral metastases diagnosed during life are rare. We have encountered, on intravenous urography and retrograde pyelography, a rather characteristic appearance of multiple undulating areas of narrowing produced by diffuse lymphatic involvement of the periureteral fat in occult prostatic carcinoma with normal regional lymph nodes. Over a 10-year period, six such patients were reviewed. Four patients presented with colicky pain and three proceeded rapidly to either azotemia or acute anuria. A fifth patient with vague symptoms were into acute anuria. In three patients the prostate gland felt benign, but four-corner biopsies of the prostate disclosed the occult malignancy. The serum acid phosphatase was normal in two patients and only slightly elevated in four. In addition to ureteral lymphangitic involvement, five of the six patients had bone or lung involvement. All areas responded well to orchidectomy and estrogen therapy. The survival time was surprisingly good with two patients alive and well after 5 years.
 ...
PMID:Lymphangitic ureteral metastases from prostatic carcinoma. 719 21

In 11 patients with Horton's headache morphological investigations (differential white blood cell count), cytoenzymatic determinations (alkaline and acid phosphatase, non-specific esterase) and cytoimmunological tests (IgM and IgG binding) were carried out on capillary blood neutrophils obtained from the area of pain, non-painful area of the skin on the head on the contralateral side, and from the finger. The observed changes suggest an active participation of neutrophils in the pathological mechanism of Horton's headache and anaphylactoidal background of the disease.
 ...
PMID:[Cytoenzymatic and cytoimmunological changes in capillary blood neutrophils of patients with Horton's headache]. 745 19

In a retrospective analytical study the authors evaluated in 86 patients, mean age 69 years (range 55-85 years), with a newly diagnosed untreated prostate carcinoma the sensitivity, specificity, positive and negative predictive value of specific prostatic antigen (PSA), acid phosphatase (AP), alkaline phosphatase (AP') and pain in relation to possible affection of bones by secondaries. The authors found a highly negative predictive value for assessment of bone metastases when PSA values were lower than 10 ng/ml (96%), at levels under 20 ng/ml (94%) and a highly positive predictive value at levels higher than 50 ng/ml (97%). When AP and AP' are negative and there is no pain the occurrence of secondaries is of low probability. These results make it possible to differentiate some patients where scintigraphy of the skeleton is not inevitable. This procedure can be applied above all in patients where radical prostatectomy is not indicated.
 ...
PMID:[Levels of prostate-specific antigen, acid phosphatase, alkaline phosphatase and pain in the prediction of bone metastases in patients with newly diagnosed prostatic carcinoma]. 753 51

A total of 20 patients with hormone-refractory prostate carcinoma entered a pilot study of combination chemotherapy based on the EAP (etoposide, Adriamycin and cisplatin) regimen, in which Adriamycin was replaced by pirarubicin, a less cardiotoxic derivative of Adriamycin. The response was assessed by criteria modified from those of the National Prostatic Cancer Project: prostate-specific antigen was employed instead of acid phosphatase. Of 18 evaluable patients, 6 achieved a partial response, 5 had stable disease, and in 7 the disease had progressed during therapy; thus, the overall response rate was 33.3% [95% confidence interval (CI) 11.5-55.1%]. Significant pain alleviation and performance status improvement were obtained in 5 of 12 patients (41.7%; CI 13.8-69.6%) and 3 of 13 patients (23.1%; CI 0.2-46.0%), respectively. Although myelosuppression was moderate to severe, no chemotherapy-related deaths or bacteriologically documented sepsis occurred; nor was there any clinical cardiotoxicity. All the responding patients received maintenance chemotherapy with etoposide thereafter. At present, the median duration of response is 33 weeks (range: 23-91 weeks) and the median survival period for all patients is 42 weeks (range: 27(+)-136 weeks), with 12 deaths. In spite of the small number of patients treated, these results suggest that this chemotherapy regimen is active in advanced hormone-refractory prostate carcinoma.
 ...
PMID:Treatment of advanced hormone-refractory prostate carcinoma with a combination of etoposide, pirarubicin and cisplatin. 780 81


<< Previous 1 2 3 4 5 6 Next >>